MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Hutchmed lung cancer treatment accepted for review in China

ALN

Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

If accepted, the Hong Kong-based developer of treatments for cancer and immunological diseases said that the new label indication for savolitinib will be expanded to include treatment-naive patients in China.

A treatment-naive patient is someone who has not received any treatment.

Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. ‘

More than a third of the world’s lung cancer patients are in China,’ Hutchmed said.

Shares in Hutchmed were flat at $16.69 each in London on Thursday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.